# HCRTR1

## Overview
The HCRTR1 gene encodes the hypocretin receptor 1, a G-protein-coupled receptor (GPCR) that plays a pivotal role in the regulation of sleep, wakefulness, and various behavioral processes. This receptor is primarily expressed in the brain, particularly in regions such as the hypothalamus, locus coeruleus, and ventral tegmental area, where it binds to the neuropeptides orexin-A and orexin-B. As a GPCR, hypocretin receptor 1 is involved in multiple signaling pathways through its interaction with various G-protein families, influencing physiological processes such as arousal, appetite, and stress response (Sutcliffe2000The; Li2020The). The receptor's function and its genetic variations have been linked to several neurological and psychiatric conditions, including migraine, mood disorders, and aggressive behavior, underscoring its significance in both normal and pathological states (Rainero2011Evidence; Harro2019Orexinhypocretin).

## Structure
The HCRTR1 gene encodes the hypocretin receptor 1, a G-protein-coupled receptor (GPCR) involved in the regulation of sleep and wakefulness. The receptor is characterized by the typical GPCR structure, which includes seven transmembrane helices, extracellular and intracellular loops, and a cytoplasmic tail (Thompson2014OX1). The intracellular loops and C-terminus are crucial for G protein coupling, which can involve multiple G proteins such as Gi, Go, Gs, and Gq (Thompson2014OX1).

A notable feature of the HCRTR1 receptor is a non-synonymous polymorphism in exon 7, resulting in an isoleucine to valine substitution at position 408 (Ile408Val) in the cytoplasmic tail. This region is a potential binding site for G proteins, which may influence intracellular signal transduction (Rainero2011Evidence). The functional impact of this polymorphism on receptor interactions and signaling remains unclear (Thompson2014OX1).

Post-translational modifications such as glycosylation and phosphorylation may affect the receptor's function and signaling, although specific details on these modifications for HCRTR1 are not provided in the context (Thompson2014OX1). The receptor's structure and function are subjects of ongoing research to better understand its role in physiological processes.

## Function
The HCRTR1 gene encodes the hypocretin receptor 1, a G-protein-coupled receptor that binds to the neuropeptides orexin-A and orexin-B. This receptor is primarily active in the brain, particularly in regions such as the hypothalamus, locus coeruleus, and ventral tegmental area (VTA), where it plays a crucial role in regulating wakefulness, arousal, and appetite (Sutcliffe2000The; Li2020The). 

HCRTR1 is involved in various physiological processes, including sleep-wake modulation, reward processing, and stress response. In the locus coeruleus, HCRTR1 is implicated in promoting wakefulness and suppressing REM sleep (Li2020The). The receptor also plays a role in reward-addiction processing by activating dopaminergic neurons in the VTA, which are involved in addictive behaviors and arousal (Li2020The). 

Additionally, HCRTR1 is expressed in the paraventricular thalamus and is involved in arousal-related behaviors and stress response. Antagonism of HCRTR1 can prevent the reinstatement of drug-seeking behavior and has anxiolytic effects (Li2020The). The receptor's activity in these brain regions highlights its importance in coordinating motivational activation and behavioral responses to external stimuli.

## Clinical Significance
The HCRTR1 gene, encoding the hypocretin receptor 1, has been implicated in several neurological and psychiatric conditions. Variations in this gene, particularly the rs2271933 polymorphism, have been associated with an increased risk of migraine, especially migraine without aura. The A allele of this polymorphism is linked to a higher risk of migraine, with a more pronounced effect observed in female patients (Rainero2011Evidence).

In the context of mood disorders, the same rs2271933 polymorphism has been associated with major mood disorders, including unipolar depression. The A allele is more prevalent in patients with these conditions, suggesting a genetic susceptibility linked to the HCRTR1 gene (Rainero2011Association).

The HCRTR1 gene is also associated with aggressive behavior. Individuals with the A/A genotype of the rs2271933 polymorphism exhibit higher levels of aggression and are more prone to risky behaviors such as drunk driving (Harro2019Orexinhypocretin).

These associations highlight the potential role of HCRTR1 in the pathophysiology of these conditions, possibly through its involvement in the regulation of mood, pain, and behavioral responses.

## Interactions
Hypocretin receptor 1 (HCRTR1) is known to interact with various proteins, primarily through its role as a G-protein-coupled receptor (GPCR). It couples with multiple G-protein families, including Gq, Gi/o, and Gs, which are involved in diverse signaling pathways. The receptor's interaction with Gq proteins leads to the activation of phospholipase C (PLC) and subsequent calcium (Ca2+) release, a prominent signaling mechanism for HCRTR1 (Kukkonen2013Orexinhypocretin).

HCRTR1 also interacts with β-arrestin, which plays a role in receptor desensitization and acts as a signaling scaffold for MAPK pathways. This interaction involves receptor internalization and ERK signaling (Kukkonen2013Orexinhypocretin). Additionally, HCRTR1 interacts with the dynein light chain Tctex-type 1 (Dynlt1), which affects ERK phosphorylation and potentially receptor trafficking (Kukkonen2013Orexinhypocretin).

The receptor is capable of forming homomeric and heteromeric complexes with other GPCRs, such as the CB1 cannabinoid receptor, although the physiological significance of these interactions is not fully understood (Kukkonen2013Orexinhypocretin). These interactions highlight the complex signaling capabilities of HCRTR1 and its involvement in various physiological processes.


## References


[1. (Rainero2011Association) Innocenzo Rainero, Luca Ostacoli, Elisa Rubino, Salvatore Gallone, Luigi Rocco Picci, Pierpaola Fenoglio, Elisa Negro, Carlo Rosso, Paola De Martino, Mario De Marchi, Pier Maria Furlan, and Lorenzo Pinessi. Association between major mood disorders and the hypocretin receptor 1 gene. Journal of Affective Disorders, 130(3):487–491, May 2011. URL: http://dx.doi.org/10.1016/j.jad.2010.10.033, doi:10.1016/j.jad.2010.10.033. This article has 34 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.jad.2010.10.033)

[2. (Sutcliffe2000The) J. Gregor Sutcliffe and Luis de Lecea. The hypocretins: excitatory neuromodulatory peptides for multiple homeostatic systems, including sleep and feeding. Journal of Neuroscience Research, 62(2):161–168, 2000. URL: http://dx.doi.org/10.1002/1097-4547(20001015)62:2<161::AID-JNR1>3.0.CO;2-1, doi:10.1002/1097-4547(20001015)62:2<161::aid-jnr1>3.0.co;2-1. This article has 270 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/1097-4547(20001015)62:2)

[3. (Rainero2011Evidence) Innocenzo Rainero, Elisa Rubino, Salvatore Gallone, Pierpaola Fenoglio, Luigi Rocco Picci, Laura Giobbe, Luca Ostacoli, and Lorenzo Pinessi. Evidence for an association between migraine and the hypocretin receptor 1 gene. The Journal of Headache and Pain, 12(2):193–199, February 2011. URL: http://dx.doi.org/10.1007/s10194-011-0314-8, doi:10.1007/s10194-011-0314-8. This article has 36 citations.](https://doi.org/10.1007/s10194-011-0314-8)

[4. (Harro2019Orexinhypocretin) Jaanus Harro, Kariina Laas, Diva Eensoo, Triin Kurrikoff, Katre Sakala, Mariliis Vaht, Jüri Parik, Jarek Mäestu, and Toomas Veidebaum. Orexin/hypocretin receptor gene (hcrtr1) variation is associated with aggressive behaviour. Neuropharmacology, 156:107527, September 2019. URL: http://dx.doi.org/10.1016/j.neuropharm.2019.02.009, doi:10.1016/j.neuropharm.2019.02.009. This article has 20 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.neuropharm.2019.02.009)

[5. (Thompson2014OX1) Miles D. Thompson, Henri Xhaard, Takeshi Sakurai, Innocenzo Rainero, and Jyrki P. Kukkonen. Ox1 and ox2 orexin/hypocretin receptor pharmacogenetics. Frontiers in Neuroscience, May 2014. URL: http://dx.doi.org/10.3389/fnins.2014.00057, doi:10.3389/fnins.2014.00057. This article has 42 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fnins.2014.00057)

[6. (Kukkonen2013Orexinhypocretin) J P Kukkonen and C S Leonard. Orexin/hypocretin receptor signalling cascades. British Journal of Pharmacology, 171(2):314–331, December 2013. URL: http://dx.doi.org/10.1111/bph.12324, doi:10.1111/bph.12324. This article has 157 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1111/bph.12324)

[7. (Li2020The) Shi-Bin Li and Luis de Lecea. The hypocretin (orexin) system: from a neural circuitry perspective. Neuropharmacology, 167:107993, May 2020. URL: http://dx.doi.org/10.1016/j.neuropharm.2020.107993, doi:10.1016/j.neuropharm.2020.107993. This article has 94 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.neuropharm.2020.107993)